Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Agenus logo — company profile

Agenus

Founded 1994 United States Lexington, United States 291 employees Post-IPO Debt Total: $346.14M Biotechnology, Health and Wellness +1

General Information

Company Name Agenus
Founded Year 1994
Location United States Lexington, United States
Founders / Decision Makers
Team member Team member
Employees 291
Industries Biotechnology, Health and Wellness, Medical Devices
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Agenus. To contact Agenus, visit agenusbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Agenus compare?

A PDF of Agenus and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Agenus soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company, founded in 1994 and headquartered in Lexington, MA, aims to expand patient populations benefiting from cancer immunotherapy through combination approaches. Agenus utilizes a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics), and adjuvants (through SaponiQx). The company received a significant $40.00M Post-IPO Equity investment on 11 October 2018. Agenus' mission to contribute to the field of biotechnology by focusing on immunological solutions for cancer and infectious diseases is noteworthy. For further information regarding Agenus, please visit their website at www.agenusbio.com or follow them at @agenus_bio. Additionally, the company's Community Guidelines are available at their website and at: https://agenusbio.com/community-guidelines/.

Business keywords: Immuno-oncology, Cancer Vaccines, Checkpoint Inhibitors, Immunotherapy, Cell therapy, Antibodies, GMP Manufacturing

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $75.00M 1
Ligand Pharmaceuticals
07 May 2024
Post IPO Equity $40.00M -
11 Oct 2018
Post IPO Equity $60.00M 1
Incyte
Incyte
14 Feb 2017
Post IPO Debt $100.00M -
23 Sep 2015
Post IPO Debt $21.14M -
11 Mar 2015
Post IPO Equity $35.00M -
11 Mar 2015
Post IPO Debt $5.00M -
25 Apr 2013
Post IPO Equity $10.00M 3
Iroquois Capital
Iroquois Capital, Hudson Capital Group +1
04 Aug 2009

Agenus Alternatives & Competitors

View All Alternatives
Agenus vs
Gritstone bio
Gritstone bio United States

A lean biotech company aiming to develop revolutionary immune-based treatment for various cancers.

Post-IPO Equity
33 employees
Biotechnology, Health Care
Compare Agenus vs Gritstone bio
Agenus vs
Oxford BioTherapeutics
Oxford BioTherapeutics United Kingdom

Redefining the cancer-immune synapse for novel immune checkpoint mechanisms

66 employees
Biotechnology, Health Care
Compare Agenus vs Oxford BioTherapeutics
Agenus vs
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Germany

Delivering the promise of radiopharmaceuticals to patients.

Private Equity
661 employees
Biopharma, Biotechnology
Compare Agenus vs ITM Isotope Technologies Munich SE
View all alternatives

FAQ About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody...
Agenus was founded in 1994.
Agenus is headquartered in Lexington, United States.
Agenus operates in Biotechnology, Health and Wellness and Medical Devices. Its work centres on Immuno-oncology, Cancer Vaccines, Checkpoint Inhibitors and Immunotherapy.
Agenus has approximately 291 employees.
Agenus has completed 8 funding rounds, raising a total of $346.14M. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Agenus include Gritstone bio, Oxford BioTherapeutics, ITM Isotope Technologies Munich SE, OSE Immunotherapeutics, Compass Therapeutics Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Agenus and Gritstone bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Agenus, https://bouncewatch.com/company/agenus, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes